A Novel Antibiotic Class to Treat Diabetic Ulcer Infections

治疗糖尿病溃疡感染的新型抗生素

• 批准号: 321280
• 负责人: McMaster Christopher R
• 金额: $ 43.97万
• 依托单位: Dalhousie University (Nova Scotia)
• 依托单位国家: 加拿大
• 项目类别: Operating Grants
• 财政年份: 2015
• 资助国家: 加拿大
• 起止时间: 2015-03-01 至 2020-03-01
• 项目状态: 已结题
• 来源: https://webapps.cihr-irsc.gc.ca/decisions/p/project_details.html?applId=321280&lang=en
• 关键词: Antibiotics; Diabetic Ulcer Infection; Drug Development; Pharmacology

New classes of antibiotics are a disturbingly unmet need. In 2013, antibiotic resistant bacteria were called a "catastrophic threat to the human population" and "nightmare bacteria" by Dame Sally Davies, England's Chief Medical Officer, and Thomas Frieden

新型抗生素是一个令人不安的未满足的需求。2013年，英国首席医疗官Dame Sally Davies和托马斯弗里登将抗生素耐药性细菌称为“对人类的灾难性威胁”和“噩梦细菌”